Ulcerative colitis is a chronic inflammatory bowel disease caused by an imbalance between natural defence mechanisms in the intestinal mucosa and microbes in the intestinal lumen. We hypothesise that an improvement or even normalisation of this balance may be achieved by the use of vaccines and dietary oats. The combined use of oral typhoid vaccine and cholera/ETEC-vaccine is supposed to stimulate mucosal defence factors, while dietary oats modifies the microbial environment inside the intestinal lumen. Or study aim is to show if such treatment brings symptom relief to patients with ulcerative colitis.

• Biological: Vaccine Vivotif + Vaccine Dukoral + oats

  Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.

  One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.

  Other Names:

  • Ty21a
  • Vibrio cholera O1 Ogawa, inactivated
• Biological: Vaccine Vivotif + Vaccine Dukoral
  Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.
  Other Names:

  • Ty21a
  • Vibrio cholera O1 Ogawa, inactivated
• Dietary Supplement: Oats
  One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.
• Other: Placebo
  Placebo capsules instead of Vivotif capsules Placebo mixture instead of liquid Dukoral vaccine

• 2: Experimental
  Vaccination with Vivotif and Dukoral
  Intervention: Biological: Vaccine Vivotif + Vaccine Dukoral
• 3: Experimental
  Dietary supplement with oats
  Intervention: Dietary Supplement: Oats
• 4: Placebo Comparator
  Placebo instead of vaccines No dietary supplement
  Intervention: Other: Placebo
• 1: Experimental
  Vaccination with Vivotif and Dukoral + dietary supplement with oats.
  Intervention: Biological: Vaccine Vivotif + Vaccine Dukoral + oats

Inclusion Criteria:

• ulcerative colitis of at least 4 months duration
• disease activity index score (Walmsley) >5 and </=13
• patients taking no ulcerative colitis relevant medicine, or stable doses of aminosalicylates or maximum 10mg prednisolon daily the last 2 weeks before study entry. They must remain on the same dose throughout the study (6 months).
• stool examination negative for enteric pathogens, clostridium difficile toxin and parasites

Exclusion Criteria:

• ulcerative colitis disease activity index >13
• symptoms of bowel obstruction
• other serious medical condition
• use of any of the study vaccines during the last two years
• use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first vaccine dose, or planned use during study period
• pregnant or planning to become pregnant
• breastfeeding
• chronic administration of prednisolone more than 10mg per day or steroids of equivalent dose the last 2 weeks before the first vaccine dose
• treatment with anti-tumor necrosis factor within 3 months prior to the first vaccine dose
• use of other immunosuppressants or immune modifying drugs within 30 days prior to the first vaccine dose